



(12) Translation of
european patent specification

(11) NO/EP 2544682 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 45/06 (2006.01)
A61K 31/05 (2006.01)
A61K 31/192 (2006.01)
A61K 31/337 (2006.01)
A61K 31/352 (2006.01)
A61K 31/4188 (2006.01)
A61K 36/185 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.07.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.02.10
(86)	European Application Nr.	11709175.1
(86)	European Filing Date	2011.03.11
(87)	The European Application's Publication Date	2013.01.16
(30)	Priority	2010.03.12, GB, 201004137
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	GW Pharma Limited, Sovereign House, HistonCambridge CB24 9BZ, GB-Storbritannia Otsuka Pharmaceutical Co., Ltd., 9, Kanda-Tsukasa-machi 2-chome Chiyoda-ku, Tokyo 101-8535, JP-Japan
(72)	Inventor	PAROLARO, Daniela, University of InsubriaVia Ravasi 2, I-21100 Varese, IT-Italia MASSI, Paola, University of MilanVia Festa del Perdono 7, I-20122 Milan, IT-Italia IZZO, Angelo Antonio, The University of NaplesFederico IICorso Umberto I, I-80138 Naples, IT-Italia BORELLI, Francesca, The University of NaplesFederico IICorso Umberto I, I-80138 Naples, IT-Italia AVIELLO, Gabriella, The University of NaplesFrederico IICorso Umberto I, I-80138 Naples, IT-Italia DI MARZO, Vincenzo, Institute of Biomolecular ChemistryNational Research Council of ItalyVia Campi Flegrei 34, I-80078 Pozzuoli, IT-Italia DE PETROCELLIS, Luciano, Institute of CyberneticsNational Research Council of ItalyVia Campi Flegrei 34, I-80078 Pozzuoli, IT-Italia MORIELLO, Aniello Schiano, Institute of CyberneticsNational Research Council of ItalyVia Campi Flegrei 34, I-80078 Pozzuoli, IT-Italia LIGRESTI, Alessia, Institute of Biomolecular ChemistryNational Research Council of ItalyVia Campi Flegrei 34, I-80078 Pozzuoli, IT-Italia ROSS, Ruth Alexandra, The University of AberdeenKing's CollegeRegent Walk, Aberdeen AB24 3FX, GB-Storbritannia FORD, Lesley Ann, The University of AberdeenKing's CollegeRegent Walk, Aberdeen AB24 3FX, GB-Storbritannia ANAVI-GOFFER, Sharon, The University of AberdeenKing's CollegeRegent Walk, Aberdeen AB24 3FX, GB-Storbritannia GUZMAN, Manuel, Departamento de Bioquímica y Biología Molecular IFacultad de Biología Universidad Complutense deMadridCalle José Antonio Novais 2, E-28040 Madrid, ES-Spania VELASCO, Guillermo, Departamento de Bioquímica y Biología Molecular IFacultad de Biología Universidad Complutense deMadridCalle José Antonio Novais 2, E-

28040 Madrid, ES-Spania
 LORENTE, Mar, Departamento de Bioquímica y Biología Molecular IFacultad de Biología Universidad Complutense deMadridCalle José Antonio Novais 2, E-28040 Madrid, ES-Spania
 TORRES, Sofia, Departamento de Bioquímica y Biología Molecular IFacultad de Biología Universidad Complutense deMadridCalle José Antonio Novais 2, E-28040 Madrid, ES-Spania
 KIKUCHI, Tetsuro, Otsuka Pharmaceutical Co. Limited1-7-1 Doshomachi Chuo-kuOsaka-shi, Osaka 541-0045, JP-Japan
 GUY, Geoffrey, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia
 STOTT, Colin, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia
 WRIGHT, Stephen, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia
 SUTTON, Alan, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia
 POTTER, David, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia
 DE MEIJER, Etienne, GW Pharma LimitedPorton Down Science ParkSalisbury, Wiltshire SP4 0JQ, GB-Storbritannia

(74) Agent or Attorney Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER**

(56) References
 Cited:

WO-A1-2008/144475
 GB-A- 2 384 707
 GB-A- 2 391 865
 GB-A- 2 438 682
 GB-A- 2 439 393
 GB-A- 2 448 535
 GB-A- 2 460 672
 US-A1- 2004 049 059
 LIGRESTI A ET AL: "Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, WILLIAMS AND WILKINS CO, vol. 318, no. 3, 1 January 2006 (2006-01-01), pages 1375-1387, XP002540820, ISSN: 0022-3565, DOI: DOI:10.1124/JPET.106.105247
 ANGELO A IZZO ET AL: "Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 86, no. 1, 6 September 2007 (2007-09-06), pages 89-98, XP019576399, ISSN: 1432-1440
 VELASCO GUILLERMO ET AL: "Cannabinoids and gliomas", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 36, no. 1, 1 August 2007 (2007-08-01) , pages 60-67, XP002540822, ISSN: 0893-7648, DOI: DOI:10.1007/S12035-007-0002-5 [retrieved on 2007-06-28]
 TORRES SOFIA ET AL: "A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma", MOLECULAR CANCER THERAPEUTICS, vol. 10, no. 1, January 2011 (2011-01), pages 90-103, XP9150445, ISSN: 1535-7163
 GUZMAN M: "Cannabinoids: Potential anticancer agents", NATURE REVIEWS CANCER 200310 GB, vol. 3, no. 10, October 2003 (2003-10), pages 745-755, XP009150450, ISSN: 1474-175X
 JONES S ET AL: "CANNABINOID RECEPTOR SYSTEMS: THERAPEUTIC TARGETS FOR TUMOUR INTERVENTION", EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 7, no. 6, 1 January 2003 (2003-01-01) , pages 749-758, XP008040356, ISSN: 1472-8222, DOI: DOI:10.1517/EOTT.7.6.749.22568

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Kombinasjon av fytocannabinoidene tetrahydrocannabinol (THC) og cannabidiol (CBD) sammen med temozolomid, for anvendelse i behandlingen av en gliom.
2. Kombinasjonen av fytocannabinoidene THC og CBD sammen med temozolomid for anvendelse ifølge krav 1, hvori kombinasjonen av fytocannabinoidene og temozolomidet pakkes for administrering separat, samtidig eller sekvensielt.
3. Kombinasjonen av fytocannabinoidene THC og CBD sammen med temozolomid for anvendelse ifølge krav 1 eller 2, hvori dosenivået til fytocannabinoidene er undereffektivt for behandlingen av gliomen hvis det anvendes alene.
4. Kombinasjonen av fytocannabinoidene THC og CBD sammen med temozolomidet for anvendelse ifølge kravene 1 til 3, hvori dosenivået til temozolomid er undereffektivt for behandlingen av gliomen hvis det anvendes alene.